USFDA approves Alembic Pharma Icatibant Injection for acute attacks of hereditary angioedema
Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
Vadodara: Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Firazyr Injection, 30 mg/3 mL (10 mg/mL), of Takeda Pharmaceuticals U.S.A., Inc.
Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling (edema) in various parts of the body, including the face, limbs, abdomen, and throat. These episodes are caused by a deficiency or dysfunction of C1 esterase inhibitor, a protein involved in regulating the immune response and inflammation. HAE attacks can be triggered by stress, trauma, or certain medications, and they typically last for several days
This is the first peptide product approval from the USFDA received by the Company. Icatibant Injection has an estimated market size of US$ 112 million for twelve months ending Mar 2024 according to IQVIA. Alembic has a cumulative total of 205 ANDA approvals (177 final approvals and 28 tentative approvals) from USFDA.
Read also: Alembic Pharma gets USFDA nod for Sacubitril and Valsartan Tablets for heart failure
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Read also: USFDA approves Alembic Pharma five products in over a month
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.